Several previous studies have shown the importance of cGMP signalling in mediating some of the cognitive aspects of major depressive disorders, multiple sclerosis, Huntington’s disease, as well as hepatic encephalopathy, and suggests that manipulation of cGMP/PDE/PKG pathway represents a plausible therapeutic target [27,32,33,34,35,36,37,38,39,40]. This evidence concerns the gene PRKG1 and juvenile Huntington disease.